Eli Lilly management last week highlighted the most promising drug candidates in the company’s pipeline, including two antisense-based drugs currently in the clinic for cancer (see related story, this issue). Despite Lilly’s early look at the RNAi field though its now-expired 2004 collaboration with Sirna Therapeutics, the drugs giant has yet to embrace RNAi as a therapeutic modality.
Other big players in the pharmaceutical, biotech, and medical device fields, however, have taken steps to incorporate RNAi into their drug-development efforts. Below is a snapshot of key alliances between big pharma/biotech and RNAi firms.
File Attachments
RNAi_deals_121406.htm